(Q42632917)

English

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.

scientific article published on 11 December 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

phase III clinical trial

0 references

zoledronic acid

1 reference

based on heuristic

inferred from title

Peter Barrett-Lee

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Jacinta Abraham

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Robert Coleman

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Peter Simmonds

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Hayley Timmins

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Duncan Wheatley

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Robert Grieve

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Gareth Griffiths

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Nick Murray

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

11 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

114-122

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Bisphosphonates and other bone agents for breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Cox's Regression Model for Counting Processes: A Large Sample Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Design and analysis of non-inferiority mortality trials in oncology.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Analysis of skeletal-related events in breast cancer and response to therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Bisphosphonates for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

QUALZICE: a QUALitative exploration of the experiences of the participants from the ZICE clinical trial (metastatic breast cancer) receiving intravenous or oral bisphosphonates.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2813%2970539-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(13)70539-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24332514%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42632917&oldid=1576863067"